BioSpace News Archive

The global stem cell therapy market size was exhibited at USD 10.51 billion in 2022 and is expected to hold around USD 18.7 billion by 2030, growing at a CAGR of 7.47% from 2022 to 2030.

Eigen Therapeutics, the biotech startup on a mission to make cancer easier to find and eliminate, announced today their launch.

C2N Diagnostics, LLC (“C2N”) provided today a recap of the multiple presentations at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, November 29 – December 2, 2022, in San Francisco, highlighting the clinical utility and performance of the company’s blood-based biomarkers for the evaluation of patients with cognitive impairment.

Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations.

BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

The board of directors of Medtronic plc on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year.